Camptothecin Impurity 15;Camptothecin Impurity 10;1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethenyl-4-hydroxy-, (4S)-
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Camptothecin Impurity refers to specific degradation products or synthetic byproducts associated with the antineoplastic agent Camptothecin. These compounds are critical for quality control in pharmaceutical manufacturing, ensuring the purity of the active pharmaceutical ingredient (API). The core process involves high-performance liquid chromatography (HPLC) analysis and semi-preparative purification. Key parameters include <strong>molecular formula C20H16N2O4</strong> and <strong>CAS No. 7589-83-0</strong>, which define its structural identity.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical R&D:</strong> Used as reference standards for method validation and stability testing during drug development.</li>
<li><strong>Quality Control:</strong> Essential for identifying and quantifying trace impurities in final drug formulations to meet regulatory limits.</li>
<li><strong>Toxicology Studies:</strong> Employed in safety assessments to evaluate potential genotoxicity or adverse effects of degradation products.</li>
</ul>
<h3>Precautions</h3>
<p>This substance is strictly for research use only and not approved for human clinical therapy. It requires storage in a cool, dry environment under inert atmosphere to prevent lactone ring hydrolysis. Personnel must wear appropriate PPE due to potential cytotoxicity and mutagenic risks.</p>